Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oligofer Fol is an oral solution combination of iron proteinsuccinate and calcium folinate pentahydrate, developed and marketed by ITF İlaç Sanayi ve Ticaret (the Turkish subsidiary of Italfarmaco). Iron proteinsuccinate is a succinylated iron-protein complex designed to protect the gastric mucosa by remaining insoluble in the stomach's acidic environment, subsequently dissolving and releasing iron in the alkaline environment of the duodenum for absorption. Calcium folinate provides folinic acid, a reduced form of folate that does not require the action of dihydrofolate reductase for activation. The product is indicated for the prevention and treatment of iron and folate deficiency anemias, particularly during pregnancy, the postpartum period, and lactation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oligofer Fol.